AstraZeneca PLC (AZN) Presents at European Respiratory Society (ERS) Congress TranscriptSeeking Alpha • 09/08/26
Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14%24/7 Wall Street • 09/08/26
Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trialsBusiness Wire • 09/08/26
AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopesCNBC • 09/08/26
Citi backs AstraZeneca sentiment boost after Etcamah wins accelerated FDA approvalProactive Investors • 09/07/26
AstraZeneca Secures FDA Nod for New Breast Cancer Therapy EtcamahZacks Investment Research • 09/07/26
AZN Stock Down 20% in 6 Months: How to Play After Pipeline SetbacksZacks Investment Research • 09/02/26
AZN's Tagrisso Plus Orpathys Study in First-Line NSCLC Meets GoalZacks Investment Research • 09/02/26
AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancerBusiness Wire • 09/01/26
AZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis StudyZacks Investment Research • 08/27/26
Amgen, AstraZeneca Score With Tezspire; Can They Take On Dupixent?Investors Business Daily • 08/27/26
AstraZeneca Vs. Bristol-Myers Squibb: Who's The Better Bargain For Investors?Seeking Alpha • 08/19/26